PHARMAC Decision to list eplerenone for the treatment of heart failure

An announcement from PHARMAC

We’re pleased to announce a decision to fund eplerenone (Inspra), subject to certain clinical criteria being met, in conjunction with the awarding of eplerenone bids as part of PHARMAC’s 2017/18 annual Invitation to Tender.

Full information here